
Check how the authors demonstrated that tumor-derived CD52 orchestrates a multi-layered immunosuppressive network that attenuates CD8+ T cell cytotoxicity, facilitating early immune evasion, and highlighted its value as a prognostic biomarker and therapeutic target.












